Health · 8 views
FDA approves first factor XIa inhibitor for secondary stroke prevention
The U.S.
AI Summary
The FDA approved Sunharbo (asundexian) 50 mg tablets for use with antiplatelet therapy to lower stroke risk in adults who have had a recent mild‑to‑moderate noncardioembolic ischemic stroke or a high‑risk transient ischemic attack. Sunharbo is the first factor XIa inhibitor authorized for this purpose. Its effectiveness is reduced when taken with drugs that are combined P‑gp and strong CYP3A4 inducers, so such combinations are not recommended. The drug is also not advised for patients with moderate or severe liver impairment and is not approved for stroke prevention in atrial fibrillation patients.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Medicare boost needed for Australia's 1.6 million cancer survivorsContinue reading
- Psilocybin may improve a difficult-to-treat symptom of depression, study findsContinue reading
- Nearly 1 in 10 US adults report having chronic hand eczemaContinue reading
- White House Yanks Pick for FDA ChiefContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow